Portfolio

Clinical-stage drug discovery

Ogeda is a drug development company with a chemistry service business focusing on discovery of small molecules targeting GPCRs. The companies’ lead program for the non-hormonal treatment of hot flashes is addressing a huge issue for woman worldwide and attracted the attention of Japanese based Astellas​

The investment illustrates the fund’s belief that purpose-driven R&D companies within healthcare are critical for developing novel solutions to improve the quality of life of people. The company was successfully sold to Astellas for a purchase price of €500 million plus milestones. ​